Equine herpesvirus type 1 mutant defective in glycoprotein e gene as candidate vaccine strain

Journal of Veterinary Medical Science

Volumn 71, Issue 11, 2009, Pages 1439-1448

  Tsujimura, Koji ^a   Shiose, Tomoki ^a,b   Yamanaka, Takashi ^a   Nemoto, Manabu ^a   Kondo, Takashi ^a   Matsumura, Tomio ^a  

^a EQUINE RESEARCH INSTITUTE   (Japan)

^b Japan Racing Association   (Japan)

Author keywords

Attenuated live vaccine; EHV 1; gE

Indexed keywords

VIRUS ENVELOPE PROTEIN; VIRUS VACCINE;

ANIMAL; ANIMAL DISEASE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; EQUINE HERPES VIRUS; GENE EXPRESSION REGULATION; GENETICS; HERPES VIRUS INFECTION; HORSE; HORSE DISEASE; IMMUNOLOGY; INTRAMUSCULAR DRUG ADMINISTRATION; INTRANASAL DRUG ADMINISTRATION; MUTATION;

ADMINISTRATION, INTRANASAL; ANIMALS; GENE EXPRESSION REGULATION, VIRAL; HERPESVIRIDAE INFECTIONS; HERPESVIRUS 1, EQUID; HORSE DISEASES; HORSES; INJECTIONS, INTRAMUSCULAR; MUTATION; VIRAL ENVELOPE PROTEINS; VIRAL VACCINES;

EQUID HERPESVIRUS 1; EQUIDAE;

EID: 71749115615     PISSN: 09167250     EISSN: 13477439     Source Type: Journal    
DOI: 10.1292/jvms.001439     Document Type: Article

References (31)

1. Allen, G. P., Kydd, J. H., Slater, J. D. and Smith, K. C. 2004. Equid herpesvirus 1 and equid herpesvirus 4 infections. pp. 829-859. In: Infectious Diseases of Livestock (Coetzer, J. A. W. and Tustin, R. C. eds.), Oxford University Press, Cape Town.
2. Allen, G. P., Kydd, J. H., Slater, J. D. and Smith, K. C. 1999. Advances in understanding of the pathogenesis, epidemiology and immunological control of equine herpesvirus abortion. pp. 129-146. In: Equine Infectious Diseases VIII (Wernery, U., Wade, J. F., Mumford, J. A. and Kaaden, O. R. eds.), R&W Publisher, Newmarket.
3. Breathnach, C. C., Yeargan, M. R., Sheoran, A. S. and Allen, G. P. 2001. The mucosal humoral immune response of the horse to infective challenge and vaccination with equine herpesvirus-1 antigens. Equine Vet. J. 33: 651-657.
4. Borchers, K., Thein, R. and Sterner-Kock, A. 2006. Pathogenesis of equine herpesvirus-associated neurological disease: a revised explanation. Equine Vet. J. 38: 283-287.
5. Cardwell, J., Smith, K., Newton, R., Blunden, T., Bestbier, M. and Whitwell, K. 2003. EHV paralytic disease in the south of England. Vet. Rec. 152: 441-442.
6. Chong, Y. C., Duffus, W. P., Field, H. J., Gray, D. A., Awan, A. R., O'Brien, M. A. and Lunn, D. P. 1991. The raising of equine colostrum-deprived foals; maintenance and assessment of specific pathogen (EHV-1/4) free status. Equine Vet. J. 23: 111-115.
7. Gilkerson, J. R. and Barrett, E. J. 2008. Equine herpesvirus neurological disease. Equine Vet. J. 40: 102-103.
8. Goehring, L. S., van Winden, S. C., van Maanen, C. and Sloet van Oldruitenborgh-Oosterbaan, M. M. 2006. Equine herpesvirus type 1-associated myeloencephalopathy in The Netherlands: a four-year retrospective study (1999-2003). J. Vet. Intern. Med. 20: 601-607.
9. Goehring, L. S., van Maanen, C. and Sloet van Oldruitenborgh-Oosterbaan, M. M. 2005. Neurological syndromes among horses in The Netherlands. A 5 year retrospective survey (1999-2004). Vet. Q. 27: 11-20.
10. Goodman, L. B., Loregian, A., Perkins, G. A., Nugent, J., Buckles, E. L., Mercorelli, B., Kydd, J. H., Palù, G., Smith, K. C., Osterrieder, N. and Davis-Poynter, N. 2007. A point mutation in a herpesvirus polymerase determines neuropathogenicity. PLoS Pathog. 3: 1583-1592.
11. Goodman, L. B., Wagner, B., Flaminio, M. J., Sussman, K. H., Metzger, S. M., Holland, R. and Osterrieder, N. 2006. Comparison of the efficacy of inactivated combination and modifiedlive virus vaccines against challenge infection with neuropathogenic equine herpesvirus type 1 (EHV-1). Vaccine 24: 3636-3645.
12. Henninger, R W., Reed, S. M., Saville, W. J., Allen, G. P., Hass, G. F., Kohn, C. W. and Sofaly, C. 2007. Outbreak of neurologic disease caused by equine herpesvirus-1 at a university equestrian center. J. Vet. Intern. Med. 21: 157-165.
13. rd International Conference on Equine Infectious iseases (Bryans, J. T. and Gerber, H. eds.), S. Karger AG, Basel.
14. Kaashoek, M. J., Rijsewijk, F. A., Ruuls, R. C., Keil, G. M., Thiry, E., Pastoret, P. P. and van Oirschot, J. T. 1998. Virulence, immunogenicity and reactivation of bovine herpesvirus 1 mutants with a deletion in the gC, gG, gI, gE, or in both the gI and gE gene. Vaccine 16: 802-809.
15. Kydd, J. H., Townsend, H. G. and Hannant, D. 2006. The equine immune response to equine herpesvirus-1: the virus and its vaccines. Vet. Immunol. Immunopathol. 15: 15-30.
16. Kydd, J. H., Wattrang, E. and Hannant, D. 2003. Pre-infection frequencies of equine herpesvirus-1 specific, cytotoxic T lymphocytes correlate with protection against abortion following experimental infection of pregnant mares. Vet. Immunol. Immunopathol. 96: 207-217.
17. Lawrence, G. L., Gilkerson, J., Love, D. N., Sabine, M. and Whalley, J. M. 1994. Rapid, single-step differentiation of equid herpesviruses 1 and 4 from clinical material using the polymerase chain reaction and virus-specific primers. J. Virol. Methods 47: 59-72.
18. Liang, X., Chow, B. and Babiuk, L. A. 1997. Study of immunogenicity and virulence of bovine herpesvirus 1 mutants deficient in the UL49 homolog, UL49.5 homolog and dUTPase genes in cattle. Vaccine 15: 1057-1064.
19. Mars, M. H., de Jong, M. C., Franken, P. and van Oirschot, J. T. 2001. Efficacy of a live glycoprotein E-negative bovine herpesvirus 1 vaccine in cattle in the field. Vaccine 19: 1924-1930.
20. Matsumura, T., Kondo, T., Sugita, S., Damiani, A. M., O'Callaghan, D. J. and Imagawa, H. 1998. An equine herpesvirus type 1 recombinant with a deletion in the gE and gI genes is avirulent in young horses. Virology 242: 68-79.
21. Matsumura, T., O'Callaghan, D. J., Kondo, T. and Kamada, M. 1996. Lack of virulence of the murine fibroblast adapted strain, Kentucky A (KyA), of equine herpesvirus type 1 (EHV-1) in young horses. Vet. Microbiol. 48: 353-365.
22. Matsumura, T., Sugiura, T., Imagawa, H., Fukunaga, Y. and Kamada, M. 1992. Epizootiological aspects of type 1 and type 4 equine herpesvirus infections among horse populations. J. Vet. Med. Sci. 54: 207-211.
23. Mayer, A. 1970. Vaccination of horses against equine herpesvirus 1 infection. pp. 41-45. In: Proceedings of the Second International Conference on Equine Infectious Diseases. (Bryans, J. T. and Gerber, H. eds.), S. Karger AG, Basel.
24. Minke, J. M., Audonnet, J. C. and Fischer, L. 2004. Equine viral vaccines: the past, present and future. Vet. Res. 35: 425-443.
25. Müller, T., Bätza, H. J., Schlüter, H., Conraths, F. J. and Mettenleiter, T. C. 2003. Eradication of Aujeszky's disease in Germany. J. Vet. Med. B Infect. Dis. Vet. Public Health 50: 207-213.
26. Pette, J. 1966. Development of a living virus vaccine against rhinopneumonitis of horses. pp. 112-116. In: Proceedings of the First International Conference on Equine Infectious Diseases (Bryans, J. T. ed.), The Grayson Foundation, Lexington.
27. Slater, J. D., Gibson, J. S. and Field, H. J. 1993. Pathogenicity of a thymidine kinase-deficient mutant of equine herpesvirus 1 in mice and specific pathogen-free foals. J. Gen. Virol. 74: 819-828.
28. Telford, E. A., Watson, M. S., McBride, K. and Davison, A. J. 1992. The DNA sequence of equine herpesvirus-1. Virology 189: 304-316.
29. Tsujimura, K., Yamanaka, T., Kondo, T., Fukushi, H. and Matsumura, T. 2006. Pathogenicity and immunogenicity of equine herpesvirus type 1 mutants defective in either gI or gE gene in murine and hamster models. J. Vet. Med. Sci. 68: 1029-1038.
30. van Oirschot, J. T., Kaashoek, M. J., Maris-Veldhuis, M. A., Weerdmeester, K. and Rijsewijk, F. A. 1997. An enzymelinked immunosorbent assay to detect antibodies against glycoprotein gE of bovine herpesvirus 1 allows differentiation between infected and vaccinated cattle. J. Virol. Methods 67: 23-34.
31. van Oirschot, J. T., Houwers, D. J., Rziha, H. J. and Moonen, P. J. 1988. Development of an ELISA for detection of antibodies to glycoprotein I of Aujeszky's disease virus: a method for the serological differentiation between infected and vaccinated pigs. J. Virol. Methods 22: 191-206.